Latest News from ASCO in Action

Latest News from ASCO in Action

September 26, 2014

On September 16, 2014, Genentech notified hospital pharmacies of a change in distribution channels for its infused cancer medicines.  Beginning October 1, Avastin, Herceptin and Rituxan will be available to hospitals and clinics only through authorized specialty distributors.  Hospital pharmacies are appealing to the company to reconsider, citing serious concerns about the resulting disruption in care for cancer patients.

September 26, 2014

ASCO has submitted comments to the Food and Drug Administration on the agency’s recent guidance document on informed consent processes for clinical research.

September 23, 2014

ASCO's Government Relations Committee, as part of the society’s federal advocacy efforts, held a reception for members of Congress and congressional staff at the U.S. Capitol in Washington, D.C. During the event, ASCO members talked with lawmakers about various issues of concern in oncology care, including efforts to repeal the Sustainable Growth Rate, and to support and invest in medical research through increased funding for the National Institutes of Health.

ASCO's ACT Network

ASCO's ACT Network

ALERT CONGRESS TODAY! Use ASCO's ACT Network to contact your elected officials on important policy issues impacting cancer care. 

ASCO Issue Backgrounders

ASCO Issue Backgrounders

ASCO offers issue backgrounders to help provide an overview of the major policy issues that impact patients with cancer and the physicians who care for them. The issue backgrounders cover topics such as reimbursement, health equity, cancer research funding, and more.

Click here to read the backgrounds and help develop your understanding of cancer policy issues.

NIH Funding Educational Series

NIH Funding Educational Series

ASCO explores the decade-long decline in federal funding for cancer research – and why this decline must be reversed. Read more here.